Taken together, these results show that moxifloxacin acts as a splicing modifier, promoting the inclusion of SMN2 Ex7 as it was previously showed in SMA fibroblasts in a dose-dependent manner [15]. This evidence concerns the gene SMN2 and proximal spinal muscular atrophy.